Isomorphic Labs says its November 17 Series C was co-led by Greenoaks and Sequoia Capital. Funds will support IsoDDE, drug candidates and R&D infrastructure. Reported positive results are largely preclinical; human safety and efficacy still need validation.
Synced examines CataX's proposed clinical-development organization, with one lead coordinating specialist agents, external experts and quality review. The Mithril example remains preclinical; organizational efficiency is distinct from human efficacy and safety.
INFevo discloses a pre-A round exceeding RMB 100 million for model R&D, research products and team development. The report describes OCOO-T's experimental metrics and platform plans; results apply to the stated datasets and tasks, not clinical efficacy.